Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 8/20 | 0.49 |
| ▸ | THRB | P10828 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4556556 | 0.87 | THRA (0.52) | THRATHRBHDAC3HDAC1HDAC2 | |
| SCHEMBL4556782 | 0.85 | CYSLTR2 (0.51) | THRATHRBKDM4ECYSLTR2CYSLTR1 | |
| SCHEMBL4557812 | 0.81 | THRA (0.47) | THRATHRBMEN1ALDH1A1KMT2A | |
| SCHEMBL1961888 | 0.81 | MAOB (0.53) | KDM4EALDH1A1MAOB | |
| SCHEMBL4556784 | 0.79 | MEN1 (0.46) | THRATHRBMEN1ALDH1A1KMT2A | |
| SCHEMBL7770564 | 0.77 | KDM4E (0.43) | THRATHRBKDM4EALDH1A1TSHR | |
| SCHEMBL29056506 | 0.77 | RXFP1 (0.45) | THRATHRBKDM4EMEN1ALDH1A1 | |
| SCHEMBL7514252 | 0.77 | THRA (0.62) | THRATHRBMEN1ALDH1A1KMT2A | |
| SCHEMBL27355171 | 0.76 | THRA (0.54) | THRATHRBHDAC3HDAC1HDAC2 | |
| SCHEMBL19583373 | 0.75 | THRA (0.52) | THRATHRBKDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507549-B2 | Methods for synthesizing glycinols, glyceollins I and II and isoflavenes and chromanes using a Wittig reaction, and compositions made therewith | THE UNIVERSITY OF TOLEDO (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | THE UNIVERSITY OF TOLEDO | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115942-A1 | Methods for Synthesizing Glycinols, Glyceollins I and II and Isoflavenes and Chromanes Using A Wittig Reaction, and Compositions Made Therewith | UGGT1, GCG, UGT8 | THRA 3562/4885THRB 3674/4885KDM4E 3366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.